Active Clinical Trials

VeraCept IUD Study

 

This study is closed to recruitment, and is no longer screening new participants.

 

This study is being conducted at the University of Pennsylvania to research a low-dose copper contraceptive that is placed in the uterus and is intended to prevent pregnancy, known as VeraCept. This device is experimental and is being developed as a possible method of long-acting reversible contraception. “Experimental” means that VeraCept has not yet been approved by the Food and Drug Administration (FDA) for sale in the United States. 

The study will investigate the safety and effectiveness of VeraCept in preventing pregnancy. We will also be looking at any effects on menstrual cycle periods and bleeding, and assess any side effects. Study participation involves 6 visits over approximately one year, as well as monthly telephone calls and completion of a daily diary chart. 

Qualified participants:

  • Healthy women ages 18 - 40
  • Have regular menstrual periods
  • Willing to use the study device as their only method of birth control during the study
  • Not seeking pregnancy for at least 1 year
  • Sexually active with a regular male partner

Qualified participants will receive:

  • Medical exams
  • $50-75 per completed study visit (a maximum of $850)
  • Investigational intrauterine contraceptive device

If you are interested in participating in this study, complete the online pre-screener here or contact Arden McAllister at 215-662-3532 or arden.mcallister@uphs.upenn.edu for more information.

Principal Investigator:
Dr. Courtney Schreiber, MD, MPH

Study Coordinator:
Arden McAllister
arden.mcallister@uphs.upenn.edu
215-662-3532

Clinical Trials Now Recruiting!

Active Clinical Trials

Fertility and the BRCA gene

Studies on the Epigenetic Regulation of Human Pregnancy in  Fertile and Infertile Couples and Placental Parameters Sub-Study

Infertility

Paid research study seeking healthy women who are not at risk for pregnancy

Infertility study

Non-hormonal intrauterine device